# Insulin medicines: Supply chain

Source page: https://www.materialinsights.org/products/p_insulin_medicines/prod-supply/

#### Output and value

World output and its value, with year and source

| Measure | Value | Unit | Year | Source |
|---|---|---|---|---|
| Novo Nordisk sales of insulin (one company's sales, not world output) | 53,137 | DKK million | 2025 | ^[12] |
| Sanofi net sales of Lantus (insulin glargine; one company's sales; table value, Appendix 1 net sales table) | 1733 | EUR million | 2025 | ^[13] |
| Sanofi net sales of Toujeo (insulin glargine; one company's sales; table value, Appendix 1 net sales table) | 1345 | EUR million | 2025 | ^[13] |

as of 2026-11-13

#### Where it is made

Country shares of world output

| Country | Measure | Year | Source |
|---|---|---|---|
| India | A press report says Wockhardt sells human insulin in India and exports it to around ten countries, and Biocon, Eris and Lupin sell lower-cost glargine in India; no country shares of world output were found | 2026 | ^[10] |
| Malaysia | Biocon has invested $600 million since 2011 in its Johor plant, as reported | 2026 | ^[10] |

as of 2026-11-13

#### Main companies

The largest makers and their shares

| Company | Country | Share | Measure | Year | Source |
|---|---|---|---|---|---|
| Novo Nordisk | Denmark | – | Insulin sales of DKK 53,137 million in 2025 (one company's sales); headquarters in Bagsværd, Denmark | 2025 | ^[12] |
| Sanofi | France | – | Lantus €1,733 million and Toujeo €1,345 million net sales in 2025 (table values); global headquarters in Paris | 2025 | ^[13]^[19] |
| Eli Lilly and Company | United States of America | – | Began selling Iletin in 1923, in Indianapolis, Indiana; no insulin sales figure found in a source opened | 1923 | ^[3]^[4] |
| Eris Lifesciences | India | 24 | Share of India's regular human insulin cartridge market, up from 13% over FY26, as Eris told investors (the company's own figure, reported in the press; one segment); registered office in Ahmedabad | 2026 | ^[10]^[20] |

as of 2026-11-13

#### Supply chains of the main makers

For the top three to five producing countries and India: share, where inputs and components come from, main makers and how variants differ

| Country | Inputs from | Makers | How variants differ | Year | Source |
|---|---|---|---|---|---|
| India | Not stated in the pages opened | Biocon, Eris and Lupin (lower-cost glargine); Wockhardt (human insulin, exported to about ten countries); Novo Nordisk, which a press report says told its marketing partner Abbott India that human insulin in Penfill cartridges and FlexPen devices would be withdrawn once stock ran out; Sanofi's Lantus remains the reference basal insulin | Human insulin such as Human Mixtard is under price control, the report says; the once-weekly analogue Awiqli is on sale | 2026 | ^[10] |

as of 2026-11-13

#### Industries that make it

The industries and kinds of firm that make it
 Made by

- [Innovator pharma and biotech companies](https://www.materialinsights.org/industries/pharmaceuticals/) World Three multinational companies control more than 90% of the insulin market, WHO said in 2021 ^[1]; Novo Nordisk and Sanofi sales are in ^[12]^[13].
- [Finished-dose formulators (branded and generic)](https://www.materialinsights.org/industries/pharmaceuticals/) India A press report says Biocon, Eris and Lupin sell lower-cost glargine in India and Wockhardt sells human insulin ^[10].

as of 2026-11-13

#### Rules and standards

Labels, efficiency and emission standards, producer responsibility, bans and tariffs

| Rule | Place | Year | What it does | Source |
|---|---|---|---|---|
| NPPA ceiling prices for human insulin injections (price fixation orders S.O. 2734(E) and 2735(E)) | India | 2012 | Government review orders confirm that the NPPA orders of 16 November 2012 fixed ceiling prices for human insulin injections ^[18]; a press report says the ceiling applied irrespective of brand, with separate ceilings for domestic and imported insulin, and that Biocon and Wockhardt objected to the higher ceiling for imports ^[11] | ^[18]^[11] |
| Price control on human insulin, such as Human Mixtard | India | 2026 | A 2026 press report says Human Mixtard sits under price control and earns close to Rs 800 crore a year | ^[10] |
| WHO prequalification of human insulin (pilot procedure) | World | 2022 | WHO prequalified the first human insulins on 28 September 2022; full assessment includes WHO inspection of the relevant manufacturing facilities | ^[7]^[8] |

as of 2026-11-13

#### India

India's output, trade, makers and rules in a short paragraph

About 6 million people in India were on insulin therapy in 2026, a press report says ^[10]. Biocon, Eris and Lupin sell lower-cost glargine and Wockhardt sells human insulin; the report says Novo Nordisk is withdrawing human insulin in Penfill cartridges and FlexPen devices ^[10]. NPPA orders of November 2012 fixed ceiling prices for human insulin injections ^[18]^[11], and Human Mixtard is under price control ^[10]. No source opened gives India's output, trade or import share.

as of 2026-11-13

#### Trade

World exports, the top exporters and importers and India, from UN Comtrade by HS code (worked out by the site)

| Flow | Value | Unit | Volume | Unit | Year | Source |
|---|---|---|---|---|---|---|
| World exports | 5.28 | USD billion | 23.3 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Average export value (calculated) | 226.9 | USD per kg | – | – | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: Germany (40.9% of world exports) | 2.16 | USD billion | 1.5 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: France (29.3% of world exports) | 1.55 | USD billion | 7.4 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: United States (9.8% of world exports) | 0.52 | USD billion | 1.4 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: India (2.8% of world exports) | 0.15 | USD billion | 2.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: Hungary (2.1% of world exports) | 0.11 | USD billion | 0.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| India exports (rank 4, 2.8% of world) | 0.15 | USD billion | 2.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| India imports (rank 7, 2.9% of world) | 0.19 | USD billion | 0.9 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Importer: United States (14.8% of world imports) | 0.95 | USD billion | 5.2 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Importer: Germany (12.3% of world imports) | 0.79 | USD billion | 1.8 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Importer: France (6.5% of world imports) | 0.42 | USD billion | 1.9 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |

Worked out from data

#### Sources

1. [New WHO report maps barriers to insulin availability and suggests actions to promote universal access](https://www.who.int/news/item/12-11-2021-new-who-report-maps-barriers-to-insulin-availability-and-suggests-actions-to-promote-universal-access) World Health Organization, 2021, news item of 12 November 2021
2. [Insulin Development and Commercialization](https://www.Acs.Org/content/dam/acsorg/education/whatischemistry/landmarks/insulin/insulin-booklet.pdf) American Chemical Society (National Historic Chemical Landmark), 2023, landmark booklet, © 2023 American Chemical Society
3. [Manufactured insulin, 'Iletin', United States, 1923 | Science Museum Group Collection](https://collection.sciencemuseumgroup.org.uk/objects/co143500/manufactured-insulin-iletin-united-states-1923-insulin) Science Museum Group, object record co143500
4. [First human insulins prequalified](https://extranet.who.int/pqweb/news/first-human-insulins-prequalified) World Health Organization, Prequalification of Medical Products, 2022, news item of 28 September 2022
5. [Human Insulin | WHO - Prequalification of Medical Products](https://extranet.who.int/prequal/medicines/human-insulin) World Health Organization, Prequalification of Medical Products, prequalification page for human insulin; the page shows no start date for the pilot
6. [India 2030: Who Supplies the Next 10 Million?](https://www.biospectrumindia.com/features/18/28731/india-2030-who-supplies-the-next-10-million.html) BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
7. [1 insulin price cap for all brands](https://www.business-standard.com/article/companies/1-insulin-price-cap-for-all-brands-112112100017_1.html) Business Standard (Sushmi Dey), 2012, article of 21 November 2012
8. [Financial performance - Novo Nordisk Annual Report 2025](https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html) Novo Nordisk, 2025, insulin sales sentence; page footer gives Novo Nordisk HQ, Novo Alle 1, 2880 Bagsværd, Denmark
9. [2025: strong sales and EPS growth.](https://www.sanofi.com/assets/dotcom/pressreleases/2026/2026-01-29-06-30-00-3228191-en.pdf) Sanofi, 2026, full-year 2025 results press release, Paris, January 29, 2026; Appendix 1, FY 2025 net sales table
10. [Review orders on the review applications of M/s Eli Lilly & Co. (India) Pvt. Ltd. against NPPA price fixation orders for insulin (File No. 31015/17/2012-PI.I and others)](https://www.pharma-dept.gov.in/sites/default/files/RO26022013.pdf) Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals, 2013, order of 15 January 2013 on S.O. 2734(E) and 2735(E); the document gives no price amounts
11. [Press Release: Sanofi moves into its new Paris global headquarters](https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-28-09-00-00-2562820) Sanofi, 2022, press release of 28 November 2022
12. [Outcome of the board meeting held today, i.e., Wednesday, November 12, 2025](https://nsearchives.nseindia.com/corporate/ERIS_12112025182848_Outcomesigned.pdf) Eris Lifesciences Limited (filing to the National Stock Exchange of India), 2025, letterhead: Registered & Corporate Office, Bodakdev, Ahmedabad

## Other sections

- [Summary](https://www.materialinsights.org/products/p_insulin_medicines/index.md)
- [Working](https://www.materialinsights.org/products/p_insulin_medicines/prod-working/index.md)
- [Bill of materials](https://www.materialinsights.org/products/p_insulin_medicines/prod-bom/index.md)
- [Use case](https://www.materialinsights.org/products/p_insulin_medicines/prod-use/index.md)
- [Footprint](https://www.materialinsights.org/products/p_insulin_medicines/prod-footprint/index.md)
- [Evolution](https://www.materialinsights.org/products/p_insulin_medicines/prod-evolution/index.md)
- [Interventions](https://www.materialinsights.org/products/p_insulin_medicines/prod-interventions/index.md)
